Nov 09, 2020 / 07:00PM GMT
Martin Douglas Auster - Crédit Suisse AG - Research Division - Research Analyst
Okay. Hey, everybody. I'm Marty Auster. I am the lead SMID cap biotech analyst here at Crédit Suisse. You are joining us for the Esperion presentation at the 29th Annual Crédit Suisse Healthcare Conference in the first, and hopefully, the only virtual health care conference we'll be hosting.
I've got Tim Mayleben, CEO; and Rick Bartram, CFO, on the call today. And Tim, Rick, thanks a lot for joining us. Really happy to have you here.
I'll let you kick off and say hi, and you can tell us what it was like trying to launch a drug during the pandemic.
Timothy M. Mayleben - Esperion Therapeutics, Inc. - President, CEO & Director
Yes. Thanks, Marty. Thank you for hosting us today and definitely look forward to a nice conversation here this afternoon. I think maybe I'll just start out by saying, no denying, this has been a challenging unprecedented environment. I think we've exhausted superlatives and adjectives to describe what the COVID
Esperion Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 10, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers